Last reviewed · How we verify

NCT04979143: Moses 2

Moses Vaporization: Is Use of Moses 2.0 in Holmium Laser Ablation of the Prostate More Efficient

Terminated NA Last updated 24 August 2025
What this trial tests

NA trial testing Surgical Approach in Benign Prostatic Hyperplasia in 19 participants. Terminated before completion.

Timeline
28 November 2022
Primary endpoint
12 May 2025
7 July 2025

Quick facts

Lead sponsorUniversity of Kansas Medical Center
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment19
Start date28 November 2022
Primary completion12 May 2025
Estimated completion7 July 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Kansas Medical Center

Who can join

18 and older, male only, with Benign Prostatic Hyperplasia or Lower Urinary Tract Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine if use of Moses 2.0 results in improved ablation efficiency during holmium laser vaporization of the prostate. To determine if use of Moses 2.0 results in less char, improved visibility, and improved hemostasis in prostate vaporization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Surgical Approach

Trials testing the same drug.

Other recruiting trials for Benign Prostatic Hyperplasia

Currently open trials in the same condition.

Other University of Kansas Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04979143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing